Revisiting the Cost-effectiveness of Universal HPV-vaccination in Denmark Accounting for All Potentially Vaccine Preventable HPV-related Diseases in Males and Females

Overview

Journal Cost Eff Resour Alloc

Publisher Biomed Central

Date 2015 Feb 20

PMID 25694771

Citations 16

Authors

Jens Olsen

Tine Rikke Jorgensen

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this study was to assess the consequences of a national immunization program with HPV vaccine for both boys and girls in Denmark, including the prophylactic effects on all potentially vaccine preventable HPV-associated diseases in male and female.

Methods: The study focussed on the quadrivalent vaccine which protects against HPV type 6, 11, 16 and 18, and the vaccine's protection against genital warts, cervical intraepithelial neoplasia, cervical cancer, anogenital cancer (anal, penile, vaginal and vulvar cancer) and head and neck cancer (oral cavity, oropharyngeal, hypopharyngeal and laryngeal cancer) were included in the analyses. In general, the analysis was performed in two phases. First, an agent-based transmission model that described the HPV transmission without and with HPV vaccination was applied. Second, an analysis of the incremental costs and effects was performed. The model did not include naturally-acquired immunity to HPV in the simulations.

Results: In the base case result (i.e. vaccination of girls only, 85% vaccination rate, private market price at € 123 per dose ex. VAT) an ICER of 3583 €/QALY (3-dose regime) is estimated when all HPV-related diseases are taken into account. Vaccination of girls & boys vs. vaccination of girls only an ICER of 28,031 €/QALY (2-dose regime) and 41,636 €/QALY (3-dose regime) is estimated.

Conclusions: Extension of the current HPV programme in Denmark to include boys and girls is a cost effective preventive intervention that would lead to a faster prevention of cancers, cancer precursors and genital warts in men and women.

Citing Articles

Incremental net benefit of extending human papillomavirus vaccine to boys in oropharyngeal cancer burden: Meta-analysis of cost-effectiveness studies.

Pratama A, Chen S, Liao S, Su W, Yu J J Dent Sci. 2024; 19(4):2045-2056.

PMID: 39347094 PMC: 11437266. DOI: 10.1016/j.jds.2024.05.032.

Human Papillomavirus (HPV) Vaccine Coverage and Confidence in Italy: A Nationwide Cross-Sectional Study, the OBVIOUS Project.

Montalti M, Salussolia A, Capodici A, Scognamiglio F, Di Valerio Z, La Fauci G Vaccines (Basel). 2024; 12(2).

PMID: 38400170 PMC: 10891781. DOI: 10.3390/vaccines12020187.

Childhood tonsillectomy alters the primary distribution of HPV-related oropharyngeal squamous cell carcinoma.

Altenhofen B, DeWees T, Ahn J, Yeat N, Goddu S, Chen I Laryngoscope Investig Otolaryngol. 2020; 5(2):210-216.

PMID: 32337351 PMC: 7178443. DOI: 10.1002/lio2.342.

Associations between gastric cancer risk and virus infection other than Epstein-Barr virus: The protocol of a systematic review and meta-analysis based on epidemiological studies.

Wang R, Liu K, Chen X Medicine (Baltimore). 2019; 98(32):e16708.

PMID: 31393376 PMC: 6709195. DOI: 10.1097/MD.0000000000016708.

Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.

Chrysostomou A, Stylianou D, Constantinidou A, Kostrikis L Viruses. 2018; 10(12).

PMID: 30572620 PMC: 6315375. DOI: 10.3390/v10120729.

References

Zechmeister I, Freiesleben De Blasio B, Garnett G, Neilson A, Siebert U . Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009; 27(37):5133-41. DOI: 10.1016/j.vaccine.2009.06.039. View

Chesson H, Ekwueme D, Saraiya M, Watson M, Lowy D, Markowitz L . Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012; 30(42):6016-9. PMC: 6629018. DOI: 10.1016/j.vaccine.2012.07.056. View

Kreimer A, Clifford G, Boyle P, Franceschi S . Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14(2):467-75. DOI: 10.1158/1055-9965.EPI-04-0551. View

Hoots B, Palefsky J, Pimenta J, Smith J . Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009; 124(10):2375-83. DOI: 10.1002/ijc.24215. View

Olsen J, Jepsen M . Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care. 2010; 26(2):183-91. DOI: 10.1017/S0266462310000085. View

Chesson H, Ekwueme D, Saraiya M, Dunne E, Markowitz L . The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011; 29(46):8443-50. DOI: 10.1016/j.vaccine.2011.07.096. View

De Vuyst H, Clifford G, Nascimento M, Madeleine M, Franceschi S . Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2008; 124(7):1626-36. DOI: 10.1002/ijc.24116. View

Lacey C, Lowndes C, Shah K . Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006; 24 Suppl 3:S3/35-41. DOI: 10.1016/j.vaccine.2006.06.015. View

Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M . Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine. 2008; 26(44):5654-61. DOI: 10.1016/j.vaccine.2008.07.098. View

10.

Jit M, Choi Y, Edmunds W . Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008; 337:a769. PMC: 2500202. DOI: 10.1136/bmj.a769. View

11.

Giuliano A, Tortolero-Luna G, Ferrer E, Burchell A, de Sanjose S, Kjaer S . Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine. 2008; 26 Suppl 10:K17-28. PMC: 4366004. DOI: 10.1016/j.vaccine.2008.06.021. View

12.

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View

13.

Elbasha E, Dasbach E . Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010; 28(42):6858-67. DOI: 10.1016/j.vaccine.2010.08.030. View

14.

Smith J, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R . Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121(3):621-32. DOI: 10.1002/ijc.22527. View

15.

Burchell A, Richardson H, Mahmud S, Trottier H, Tellier P, Hanley J . Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol. 2006; 163(6):534-43. DOI: 10.1093/aje/kwj077. View

16.

Olsen J, Jorgensen T, Kofoed K, Larsen H . Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark. BMC Public Health. 2012; 12:1082. PMC: 3546065. DOI: 10.1186/1471-2458-12-1082. View

17.

Tota J, Chevarie-Davis M, Richardson L, deVries M, Franco E . Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med. 2011; 53 Suppl 1:S12-21. DOI: 10.1016/j.ypmed.2011.08.017. View

18.

Kim J, Goldie S . Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009; 339:b3884. PMC: 2759438. DOI: 10.1136/bmj.b3884. View

19.

Miralles-Guri C, Bruni L, Cubilla A, Castellsague X, Bosch F, de Sanjose S . Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol. 2009; 62(10):870-8. DOI: 10.1136/jcp.2008.063149. View

20.

Taira A, Neukermans C, Sanders G . Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004; 10(11):1915-23. PMC: 3328990. DOI: 10.3201/eid1011.040222. View